Swiss Market Index (SMI) – Daily Summary (2 September 2026)

  • Close: 14 334,8
  • 52‑week high: 14 669,5 (10 August 2026)
  • 52‑week low: 11 867,9 (25 September 2025)

Market Performance

On 2 September 2026 the SMI finished the trading session slightly higher, after a day that began in negative territory. Selective buying at a few counters, notably in the health‑care and energy sectors, offset broader pressure from rising oil prices and higher bond yields across Europe. The index’s performance was in line with the modest gains recorded in other major European markets, despite the negative sentiment generated by geopolitical tensions and rate‑hike fears.

Key Drivers

  1. Novartis – Positive data from phase‑III trials of Remibrutinib for relapsing multiple sclerosis generated a rally for Novartis shares, providing a clear support for the index. The company’s shares were the largest contributor to the index’s return for the day, and the news reinforced the perception that the SMI has a defensive tilt.

  2. Sector Weightings – The SMI’s composition, which includes a significant weighting in the pharmaceutical sector, meant that strong performance by Novartis had a pronounced effect on the overall index. In August, the SMI was re‑branded as the “Pharma‑Index,” a change that highlighted the importance of the health‑care sector to the index’s risk profile.

  3. External Factors – Higher oil prices and increasing bond yields weighed on European equities. The SMI’s defensive character helped it avoid a deeper decline, but the net effect was a modest gain rather than a breakout.

Comparative Context

  • European Benchmarks – The EuroStoxx 50 closed marginally lower, reflecting the broader sell‑off on geopolitical and macro‑economic concerns. The SMI’s resilience compared to its European peers underscores its defensive orientation.
  • U.S. Influence – Rising U.S. interest‑rate expectations and the subsequent increase in oil prices were cited by analysts as key external pressures, yet the SMI’s sector composition mitigated the impact.

Outlook

  • Short‑Term – The SMI is likely to remain sensitive to developments in the pharmaceutical sector and to global macro‑economic signals, particularly oil price movements and bond‑yield trends.
  • Medium‑Term – The index’s designation as the “Pharma‑Index” suggests continued emphasis on health‑care stocks; any significant change in this sector could materially affect the index’s performance.

This summary reflects all information contained in the provided input sources.